Levophed

Hypovolemic Shock, Sudden Cardiac Arrest, Hypotension + 1 more

Treatment

14 Active Studies for Levophed

What is Levophed

Norepinephrine

The Generic name of this drug

Treatment Summary

Norepinephrine is a hormone and neurotransmitter produced by the adrenal gland. It helps to regulate the body’s fight-or-flight response and is involved in the transmission of signals from the brain to parts of the body. It can also be found in plants and is used in medications to stimulate the sympathetic nervous system.

Levophed

is the brand name

image of different drug pills on a surface

Levophed Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Levophed

Norepinephrine

1982

31

Effectiveness

How Levophed Affects Patients

Noradrenaline affects the two types of adrenergic receptors (alpha-1 and alpha-2), causing the blood vessels to constrict. When tested in the lab, noradrenaline causes an increase in blood pressure because it blocks the action of the receptors, which increases the amount of resistance in the blood vessels.

How Levophed works in the body

Norepinephrine constricts blood vessels in the body, and also helps the heart beat stronger and increases the size of the arteries supplying it with blood. These effects are due to its activity on different types of adrenergic receptors.

When to interrupt dosage

The measure of Levophed is contingent upon the specified condition, such as Hypotension, Hypovolemic Shock and Hypotension. The extent of dosage is contingent upon the technique of delivery (e.g. Intravenous or Injection, solution) featured in the table beneath.

Condition

Dosage

Administration

Hypotension

, 1.0 mg/mL, 0.016 mg/mL, 0.064 mg/mL, 0.032 mg/mL, 0.04 mg/mL, 0.08 mg/mL

, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Liquid, Solution, Solution - Intravenous, Liquid - Intravenous

Hypovolemic Shock

, 1.0 mg/mL, 0.016 mg/mL, 0.064 mg/mL, 0.032 mg/mL, 0.04 mg/mL, 0.08 mg/mL

, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Liquid, Solution, Solution - Intravenous, Liquid - Intravenous

Sudden Cardiac Arrest

, 1.0 mg/mL, 0.016 mg/mL, 0.064 mg/mL, 0.032 mg/mL, 0.04 mg/mL, 0.08 mg/mL

, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Liquid, Solution, Solution - Intravenous, Liquid - Intravenous

Hypotension

, 1.0 mg/mL, 0.016 mg/mL, 0.064 mg/mL, 0.032 mg/mL, 0.04 mg/mL, 0.08 mg/mL

, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Liquid, Solution, Solution - Intravenous, Liquid - Intravenous

Warnings

Levophed has six contraindications and must not be implemented when experiencing any of the conditions in the following table.

Levophed Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Hypoxia

Do Not Combine

mesenteric or peripheral vascular thrombosis

Do Not Combine

Pulse Frequency

Do Not Combine

Hypotension

Do Not Combine

Hypercarbia

Do Not Combine

There are 20 known major drug interactions with Levophed.

Common Levophed Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylamphetamine can be increased when used in combination with Norepinephrine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when used in combination with Norepinephrine.

4-Bromo-2,5-dimethoxyamphetamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyamphetamine can be increased when used in combination with Norepinephrine.

Acebutolol

Major

The therapeutic efficacy of Acebutolol can be increased when used in combination with Norepinephrine.

Amphetamine/Dextroamphetamine

Major

The therapeutic efficacy of Amphetamine can be increased when used in combination with Norepinephrine.

Levophed Toxicity & Overdose Risk

Taking large amounts of vasopressin, or taking it in combination with other medications, can cause poor circulation in the limbs and may even lead to tissue death.

Levophed Novel Uses: Which Conditions Have a Clinical Trial Featuring Levophed?

34 active studies are investigating the potential of Levophed in treating Heart attack, Hypotension and Hypovolemic Shock.

Condition

Clinical Trials

Trial Phases

Hypovolemic Shock

9 Actively Recruiting

Phase 4, Phase 3, Not Applicable, Phase 2, Phase 1

Hypotension

0 Actively Recruiting

Sudden Cardiac Arrest

5 Actively Recruiting

Not Applicable

Hypotension

0 Actively Recruiting

Levophed Reviews: What are patients saying about Levophed?

5

Patient Review

10/16/2008

Levophed for Severely Low Blood Pressure

3

Patient Review

8/24/2010

Levophed for Severely Low Blood Pressure

2

Patient Review

11/30/2010

Levophed for Sudden Drop in Blood Pressure

When I was septic due to drinking urine, this helped my blood pressure. However, I would not recommend it because it tastes terrible.

1

Patient Review

7/10/2013

Levophed for Severely Low Blood Pressure

My father was given this treatment in the hospital and we were told he could only have it for a few days. When they stopped his drip, he died.

1

Patient Review

2/5/2018

Levophed for Severely Low Blood Pressure

I had a terrible experience with this treatment. I was already in the hospital for DKA and then the trauma team started levophed through my IV. It caused me a lot of pain.

Patient Q&A Section about levophed

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How quickly does Levophed work?

"After norepinephrine is administered intravenously, it quickly enters into a steady state. Its effects then wear off within 1-2 minutes after the infusion is stopped."

Answered by AI

What is the drug Levophed used for?

"Levophed works by constricting blood vessels and increasing blood pressure. This results in more blood flowing to the body's vital organs. Levophed is typically only given when other methods, such as IV fluids, have failed to increase blood pressure."

Answered by AI

Is Levophed a vasopressor?

"Vasopressors may be necessary for septic shock that does not improve after fluid resuscitation. Some commonly used vasopressors for septic shock include norepinephrine (Levophed), epinephrine, vasopressin, phenylephrine (Neo-Synephrine), and dopamine."

Answered by AI

How does Levophed work in the body?

"The LEVOPHED solution has a pH of 3 to 4.5 and is displacing the air in the vials with nitrogen gas. LEVOPHED has an alpha-adrenergic action that functions as a peripheral vasoconstrictor, and it also has a beta-adrenergic action that functions as an inotropic stimulator of the heart and dilator of the coronary arteries."

Answered by AI

Clinical Trials for Levophed

Image of Framingham Union Hospital/MetroWest Medical Center in Framingham, United States.

AI Assistance for Critical Illness

18+
All Sexes
Framingham, MA

This is a prospective, unmasked, randomized, multicenter clinical trial evaluating the impact of point-of-care large language model (LLM)-based decision support on diagnostic accuracy and clinical outcomes in adult medical intensive care unit (MICU) patients. Consecutive adult ICU admissions at participating community hospitals (initially MetroWest Medical Center and St. Vincent Hospital) will be screened for eligibility. Eligible patients will be randomized 1:1 to standard care or an AI-assisted group. In both arms, initial evaluation and management will follow usual practice. For patients randomized to AI assistance, de-identified admission data (history and physical, labs, imaging reports, and other relevant documentation) will be formatted and submitted to a state-of-the-art LLM (ChatGPT-5) at the time of admission. The AI-generated differential diagnosis and therapeutic recommendations will be provided to the admitting team for consideration. For the standard care arm, LLM output will be generated but not shared with clinicians. After discharge, a masked chart review will determine the "ground truth" primary diagnosis and extract outcomes including: Primary Outcome - a composite of medical errors (from time of ICU admission through day 7 of ICU stay, or ICU discharge, whichever comes first); Secondary Outcomes - 90-day mortality, ICU and hospital length of stay, and ventilator-free days.

Phase 1 & 2
Waitlist Available

Framingham Union Hospital/MetroWest Medical Center

Eric Silverman, M.D.

Image of Rush University Medical Center in Chicago, United States.

Precision-Controlled Ventilation for Cardiac Arrest

18+
All Sexes
Chicago, IL

Cardiac arrest is a life-threatening emergency that requires immediate treatment with cardiopulmonary resuscitation (CPR). While chest compressions circulate blood, manual ventilation provides oxygen to the patient. Current CPR guidelines recommend specific ventilation rates and tidal volumes, but studies show that clinicians often deliver too much or too little ventilation due to a lack of monitoring tools, potentially reducing the effectiveness of CPR and impacting survival. The PRECISION-CPR study is a multi-center, randomized controlled trial designed to evaluate whether using real-time feedback devices to precisely control ventilation during CPR can improve patient outcomes. Adult patients experiencing in-hospital cardiac arrest will be randomized to receive either standard manual ventilation guided by clinician experience or precision-controlled ventilation tailored to the patient's predicted body weight using real-time monitoring devices. The primary outcome of the study will be return of spontaneous circulation (ROSC). Secondary outcomes will include survival to hospital discharge, neurological recovery, and other clinical measures. By addressing the limitations of current ventilation practices, this study aims to generate evidence to guide future resuscitation guidelines and improve survival rates after cardiac arrest.

Waitlist Available
Has No Placebo

Rush University Medical Center

Have you considered Levophed clinical trials?

We made a collection of clinical trials featuring Levophed, we think they might fit your search criteria.
Go to Trials
Image of Kingston Health Sciences Center in Kingston, Canada.

Peripheral Vasopressors for Intensive Care Unit Patients

18+
All Sexes
Kingston, Canada

Using medications to increase blood pressure, called vasopressors, is invaluable in treating patients who have difficulty maintaining stable blood pressure. Vasopressors are usually infused through a central venous catheter (CVC), which is a flexible tube placed in the large vein of the neck, arm or groin. CVCs require a skilled clinician and often with an ultrasound to prevent complications such as a collapsed lung or bleeding. Alternatively, the infusion of vasopressors through a peripheral venous catheter (PVC), a thin tube placed in the smaller veins of the arm or hand has been avoided due to the risk of extravasation, which is the leakage of fluid to surrounding tissues. This can lead to potential tissue death requiring surgery. However, emerging research shows the safety of infusing vasopressors through a PVC, referred to as peripheral vasopressors. There is a growing interest in peripheral vasopressors for two main reasons: to expedite vasopressor initiation in patients with refractory shock and to avoid CVC placement and its potential complications. However, a standardized protocol for administration is lacking and many clinicians still avoid peripheral vasopressors due to lack of high-quality evidence. The investigators will examine the effectiveness of implementing a peripheral vasopressor protocol by conducting a feasibility study and assessing outcomes such as the safety of peripheral vasopressors and the acceptability rate of healthcare providers. By conducting this study, the investigators aim to provide the framework to conduct larger, multi-center trials and to provide high-quality data for the future use of a standardized peripheral vasopressor protocol.

Phase 2
Recruiting

Kingston Health Sciences Center

Gord Dr., PhD, MD

Image of Vanderbilt University Medical Center in Nashville, United States.

Augmented Pacing for Bradycardia

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if backup pacing at an increased rate improves hemodynamics in adults with relative bradycardia, a permanent pacemaker, and cardiogenic shock. The main question it aims to answer is: Does increasing the backup pacing rate to 100 beats per minute lead to improved cardiac index compared to a backup pacing rate of 75 beats per minute Participants who are already hospitalized in the Cardiovascular Intensive Care Unit with a permanent pacemaker and pulmonary artery catheter in place will be enrolled in this study. Participants will be exposed to each pacemaker rate in a randomized order with hemodynamics assessed after 10 minutes at each rate.

Recruiting
Has No Placebo

Vanderbilt University Medical Center

Image of London Health Sciences Center in London, Canada.

Ultrasound-Guided Management for Septic Shock

18+
All Sexes
London, Canada

The goal of this pilot clinical trial is to determine if conducting a larger study using venous excess ultrasound (VEXUS) to guide fluid management in patients with septic shock is feasible. Septic shock is a life-threatening condition where infection causes dangerously low blood pressure. While fluids are essential for treatment, too much fluid can harm the kidneys and result in the need for dialysis. The main questions it aims to answer are: 1. Is it feasible to recruit patients, obtain consent, and follow the VEXUS-guided management protocol? 2. Does VEXUS-guided management, compared with usual care, improve the health and well-being of patients with septic shock? Researchers will compare two groups: one receiving VEXUS-guided fluid management versus another receiving standard care, to assess the feasibility of a larger trial and explore whether VEXUS prevents fluid overload and kidney problems. Participants in the VEXUS group will: 1. Undergo VEXUS scans every 24 hours for 3 days 2. Receive fluid management guided by VEXUS findings (including fluid restriction or removal if we identify venous congestion) and undergo cardiac ultrasound if we identify moderate to severe congestion 3. Be monitored for 28 days to track kidney function, need for dialysis, and survival.

Phase 3
Waitlist Available

London Health Sciences Center

Have you considered Levophed clinical trials?

We made a collection of clinical trials featuring Levophed, we think they might fit your search criteria.
Go to Trials
Image of Brigham & Women's Hospital in Boston, United States.

Health Information Exchange Platform for Improving Patient Transfers

18+
All Sexes
Boston, MA

Sub-optimal transfer of clinical information during inter-hospital transfer (IHT, the transfer of patients between acute care hospitals) is common and can lead to patient harm. To address this problem, the investigators will use key stakeholder input to refine and implement an interoperable health information exchange platform that integrates with the electronic health record and improves the reliability of and access to necessary clinical information in three use cases involving transfer of patients between sending and receiving hospitals with varying levels of affiliation and health record integration. The investigators will assess the effect of this intervention on frequency of medical errors, evaluate the use and usability of this platform from the perspective of those that interact with it, and use these results to develop a dissemination plan to spread implementation and use of this platform across other similar institutions.

Waitlist Available
Has No Placebo

Brigham & Women's Hospital